source
- Tango Therapeutics reports strong early response with vopimetostat plus daraxonrasib in pancreatic cancer trialTango Therapeutics announced that its experimental epigenetic drug vopimetostat, when combined with Revolution Medicines' KRAS inhibitor daraxonrasib, produced high response rates in a small pancre…
- GSK partners with Engitix on multi-target liver researchGSK announced a collaboration with London-based Engitix to explore multiple targets for liver disease. Engitix will apply its extracellular matrix-based disease models to uncover new therapeutic op…